GLEEVEC vs RYDAPT

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. GLEEVEC and RYDAPT are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GLEEVEC	RYDAPT
Rating	70/100	70/100
Pharmacy pays	~$25.80 /30	—
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	MIDOSTAURIN
Manufacturer	Novartis	Novartis
Dosage forms	Tablet	Capsule
Drug class	Kinase Inhibitor	—
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Acute Myeloid Leukemia, Hematologic Neoplasms, Systemic Mastocytosis

gleevec rydapt

Rating

70/100

Pharmacy pays

~$25.80 /30

—

Type

Active ingredient

IMATINIB MESYLATE

MIDOSTAURIN

Manufacturer

Novartis

Dosage forms

Tablet

Capsule

Drug class

Kinase Inhibitor

—

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Acute Myeloid Leukemia, Hematologic Neoplasms, Systemic Mastocytosis

Frequently asked questions

Which is better-rated, Gleevec or Rydapt?

Gleevec and Rydapt are tied at 3.5 out of 5 by our independent rating.

What is the difference between Gleevec and Rydapt?

Gleevec contains Imatinib Mesylate, while Rydapt contains Midostaurin — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.